Two Sigma Advisers LP Buys 45,400 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Two Sigma Advisers LP raised its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 145.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,600 shares of the company’s stock after buying an additional 45,400 shares during the quarter. Two Sigma Advisers LP owned about 0.06% of Karyopharm Therapeutics worth $52,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Focus Partners Wealth bought a new position in Karyopharm Therapeutics in the 4th quarter valued at $31,000. TD Waterhouse Canada Inc. bought a new stake in Karyopharm Therapeutics during the fourth quarter valued at $32,000. Opti Capital Management LP purchased a new position in Karyopharm Therapeutics during the fourth quarter worth about $85,000. Two Sigma Investments LP grew its position in Karyopharm Therapeutics by 60.3% during the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock worth $93,000 after buying an additional 51,856 shares in the last quarter. Finally, Shay Capital LLC bought a new position in Karyopharm Therapeutics in the 4th quarter worth about $116,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Stock Up 5.4%

NASDAQ KPTI opened at $4.49 on Monday. The firm has a market capitalization of $38.79 million, a PE ratio of -4.40 and a beta of 0.23. The stock’s 50 day moving average is $5.05 and its 200 day moving average is $7.80. Karyopharm Therapeutics Inc. has a twelve month low of $3.51 and a twelve month high of $17.40.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Monday, May 12th. The company reported ($2.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.21) by $1.44. The business had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $35.12 million. On average, research analysts anticipate that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KPTI. Wall Street Zen downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 14th. HC Wainwright boosted their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Royal Bank of Canada decreased their price target on shares of Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Barclays upped their target price on shares of Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 13th. Finally, Robert W. Baird reduced their target price on shares of Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat.com, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $43.20.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).